Dai Z, Takahashi S I, Van Wyk J J, D'Ercole A J
Department of Pediatrics, University of North Carolina, Chapel Hill 27599.
Endocrinology. 1992 Jun;130(6):3175-83. doi: 10.1210/endo.130.6.1375893.
Although there is much evidence that insulin-like growth factor-I (IGF-I) is delivered to its target tissues via the circulation from distal sites of synthesis, many other observations suggest that it is synthesized in or near its target tissues and acts by autocrine and/or paracrine modalities. Studies of the mechanisms of such local actions, however, have been problematic, because in vivo studies of a single tissue are technically difficult and confounded by many variables, whereas in vitro studies of autocrine/paracrine actions have been limited by low levels of IGF-I expression and/or lack of dramatic or clearly defined responses to IGF-I. We, therefore, set about to create IGF-I expression in FRTL-5 cells, a diploid nontransformed line of rat thyroid follicular cells that have been extensively studied as a model of TSH action. The modest increase in thymidine incorporation stimulated by TSH in wild type FRTL-5 cells is markedly increased in the presence of exogenous IGF-I. By transfecting these cells with a chimeric IGF-IA gene, driven either by the mouse metallothionein-1 or IGF-II 5' genomic regulatory regions, we were able to generate stable cell lines that synthesize and secrete mature IGF-I. This was demonstrated by RIA, by Northern analysis, and by polyacrylamide gel electrophoresis characterization of the radiolabeled intracellular and extracellular products that reacted with an IGF-I antibody. The mitogenic responses to TSH in IGF-I-expressing transfected FRTL-5 cells were indistinguishable from those stimulated by TSH and IGF-I in wild type or control-transfected cells (FRTL-5 cells stably transfected with a similar transgene that does not encode IGF-I). Basal DNA synthesis was higher and the peak of thymidine incorporation was earlier in IGF-I-expressing transfected FRTL-5 cells than in wild type or control cells (18-24 h vs. 30-36 h). The concentrations of TSH that maximally stimulate the incorporation of thymidine were not altered by IGF-I expression, and transfected cells did not appear to be transformed, as judged by their inability to form colonies in soft agar. TSH-stimulated DNA synthesis was blocked in IGF-I-expressing FRTL-5 cell by a monoclonal antibody to IGF (Sm 1.2). Thus, secretion of IGF-I appears to be required for the autocrine effects observed. These IGF-I-expressing FRTL-5 cell lines provide a model in vitro system to study the intracellular processing of IGF-I and the mechanisms by which IGF-I acts in an autocrine manner.
尽管有大量证据表明胰岛素样生长因子-I(IGF-I)是通过血液循环从合成的远端部位输送到其靶组织的,但许多其他观察结果表明它是在其靶组织内或附近合成的,并通过自分泌和/或旁分泌方式发挥作用。然而,对这种局部作用机制的研究一直存在问题,因为对单一组织进行体内研究在技术上很困难,并且受到许多变量的干扰,而对自分泌/旁分泌作用的体外研究则受到IGF-I表达水平低和/或对IGF-I缺乏显著或明确界定的反应的限制。因此,我们着手在FRTL-5细胞中实现IGF-I的表达,FRTL-5细胞是大鼠甲状腺滤泡细胞的二倍体未转化细胞系,作为促甲状腺激素(TSH)作用的模型已被广泛研究。在野生型FRTL-5细胞中,TSH刺激的胸苷掺入量适度增加,在外源性IGF-I存在的情况下显著增加。通过用由小鼠金属硫蛋白-1或IGF-II 5'基因组调控区驱动的嵌合IGF-IA基因转染这些细胞,我们能够产生合成并分泌成熟IGF-I的稳定细胞系。这通过放射免疫分析(RIA)、Northern分析以及与IGF-I抗体反应的放射性标记细胞内和细胞外产物的聚丙烯酰胺凝胶电泳表征得到了证实。在表达IGF-I的转染FRTL-5细胞中,对TSH的促有丝分裂反应与野生型或对照转染细胞(稳定转染了不编码IGF-I的类似转基因的FRTL-5细胞)中TSH和IGF-I刺激的反应没有区别。在表达IGF-I的转染FRTL-5细胞中,基础DNA合成更高,胸苷掺入的峰值比野生型或对照细胞更早(分别为18 - 24小时和30 - 36小时)。最大程度刺激胸苷掺入的TSH浓度不受IGF-I表达的影响,并且转染细胞似乎没有转化,这通过它们在软琼脂中无法形成集落来判断。在表达IGF-I的FRTL-5细胞中,TSH刺激的DNA合成被一种针对IGF的单克隆抗体(Sm 1.2)阻断。因此,IGF-I的分泌似乎是观察到的自分泌效应所必需的。这些表达IGF-I的FRTL-5细胞系提供了一个体外系统模型,用于研究IGF-I的细胞内加工过程以及IGF-I以自分泌方式发挥作用的机制。